Duration of Current Statin Use and Amyotrophic Lateral Sclerosis Risk
- 21 October 2025
- journal article
- Published by Wolters Kluwer Health in Neurology
- Vol. 105 (8) , e214221
Abstract
Although hypercholesterolemia may contribute to long-term amyotrophic lateral sclerosis (ALS) risk, it can also seem as a secondary effect during the early, prediagnostic phase of the disease. We aimed to investigate the relationship between short-term and long-term use of statins and subsequent ALS risk. We designed a cohort study where information on cardiovascular risk factors among Norwegian participants in large population-based health surveys was linked to nationwide administrative data on subsequent statin use and ALS diagnosis. Duration of statin use was calculated based on cumulative defined daily doses and analyzed as time-varying exposure with 3 levels: 0-1 year (short-term), 1-5 years, and 5-17 years (long-term). In Cox regression models adjusted for sex, age, health survey participation, triglyceride and cholesterol levels, body mass index, smoking, diabetes, and hypertension, we calculated hazard ratios (HRs) for ALS according to time-varying statin exposure. In a negative control analysis, we examined whether exposure to renin-angiotensin system (RAS)-acting agents was associated with ALS risk. A total of 425,564 participants (54% women), aged 40-65 years in January 2005, were followed for a mean period of 16 years (SD 2.3) during which 493 ALS cases (44% women) were identified. Compared with no current statin use, the HR for ALS was 3.56 (95% CI 2.58-4.90) for those with 0-1 year, 0.85 (95% CI 0.59-1.23) for those with 1-5 years, and 0.67 (95% CI 0.45-1.00) for those with 5-17 years of current use. The associations between both short-term and long-term statin use and ALS risk were most evident in men, with HRs for ALS of 4.03 (95% CI 2.72-5.95) and 0.47 (95% CI 0.26-0.86), respectively. There was no clear association between either short-term or long-term use of RAS-acting agents and ALS risk. The strong association between short-term current statin use and increased ALS risk is consistent with reverse causality, where statin initiation in the prediagnostic phase may occur when lipid levels rise and individuals seek medical attention due to emerging ALS symptoms. Long-term statin use was associated with reduced risk of ALS in men.Keywords
This publication has 38 references indexed in Scilit:
- Apolipoproteins, lipids, lipid-lowering drugs and risk of amyotrophic lateral sclerosis and frontotemporal dementia: a meta-analysis and Mendelian randomisation studyJournal of Neurology, 2024
- Discovery and Exploration of Lipid-Modifying Drug Targets for ALS by Mendelian RandomizationMolecular Neurobiology, 2024
- Protective Effects of Lovastatin in a Population‐BasedALSStudy and Mouse ModelAnnals of Neurology, 2023
- Pharmacoepidemiological methods for computing the duration of pharmacological prescriptions using secondary data sourcesEuropean Journal of Clinical Pharmacology, 2021
- Statin therapy and risk of Alzheimer's and age‐related neurodegenerative diseasesAlzheimer's & Dementia: Translational Research & Clinical Interventions, 2020
- The effects of statins on microglial cells to protect against neurodegenerative disorders: A mechanistic reviewBioFactors, 2019
- Blood biomarkers of carbohydrate, lipid, and apolipoprotein metabolisms and risk of amyotrophic lateral sclerosis: A more than 20‐year follow‐up of the Swedish AMORIS cohortAnnals of Neurology, 2017
- Mortality trends of amyotrophic lateral sclerosis in Norway 1951–2014: an age–period–cohort studyJournal of Neurology, 2016
- Measuring drug exposure: concordance between defined daily dose and days' supply depended on drug classJournal of Clinical Epidemiology, 2016
- Statins: Mechanisms of neuroprotectionProgress in Neurobiology, 2009